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AbstrACt
Introduction Routine retinopathy of prematurity eye 
examinations are an important part of neonatal care, and 
mydriatic medicines are essential in dilating the pupil for 
the eye examination. There are concerns about the level 
of evidence for efficacy and safety of these mydriatic 
medicines.
Objective This review evaluates both efficacy and safety 
evidence of mydriatics used during the retinopathy of 
prematurity eye examination.
Method Systematic literature review.
results There is limited evidence guiding clinical 
practice for safety and efficacy of mydriatics. The majority 
of publications are underpowered and with an unclear to 
high level of bias. There are a wide variety of mydriatic 
regimens evaluated for efficacy and safety and multiple 
regimens associated with case reports.
Conclusions Current international guideline seems 
unnecessarily high, especially when the reviewed 
literature suggest that lower doses are effective, albiet 
from underpowered studies. The lowest effective 
combination regimen appears to be phenylephrine 1% and 
cyclopentolate 0.2% (1 drop). Microdrop administration 
of this regimen would further increase the safety profile, 
however, efficacy may not be ensured.
IntrOduCtIOn
Retinopathy is a common complication of 
prematurity, and routine screening exami-
nations are essential for timely diagnosis of 
retinopathy of prematurity (ROP). It is essen-
tial to have timely diagnosis and treatment 
of ROP, to prevent permanent blindness in 
premature neonates; however, it is essential 
that we have both safe and effective mydriatic 
regimens.
Mydriatic medicines play an essential diag-
nostic role; however, there are clinically signif-
icant risks associated with using mydriatics. 
There are concerns about the limited 
evidence that is used to support safe and 
effective mydriatic regimens, for retinopathy 
of prematurity eye examinations (ROPEE).
Various combinations of phenyleph-
rine, cyclopentolate and tropicamide are 
commonly used to prepare the neonatal for 
the ROPEE. However, the lowest effective 
dose has not been substantiated with a large 
data set nor has the evaluation of microdrop 
(md) to standard drop (d) administration. 
Pupil dilation results from standard and 
microdrop size was included in the analysis, 
and for the purposes of this paper, a standard 
drop size is considered to be approximately 
26 µL, and a microdrop size is approximately 
7 µL.1
The main safety concerns surrounding 
mydriatic medicines are ones associated with 
systemic absorption following ocular admin-
istration. Following ocular delivery, it is esti-
mated that approximately 80% of the eye 
drop volume enters the nasolacrimal duct, 
therefore gaining entry into the systemic 
circulation via the nasal mucosa.2 Systemic 
absorption of mydriatics have been associ-
ated with clinically significant, and sometimes 
life-threatening cardiovascular, respiratory, 
central nervous system (CNS) and gastro-
intestinal adverse effects. Examples of some 
adverse effects include: hypertension, hypo-
tension, tachycardia, bradycardia, apnoea, 
cardiopulmonary arrest, seizures, necrotising 
enterocolitis (NEC), sepsis and death.
Management of these side effects are 
challenging and premature infants have 
less ability to cope with the associated prob-
lems. Management of side effects in prema-
ture infants born in the developing world 
is of great concern as they are likely to have 
reduced access to care manage the associated 
complications.
International guidelines play an essential 
role in directing best practice worldwide. The 
two readily available international guidelines 
for ROPEE are the UK Guideline for the 
Screening and Treatment of Retinopathy of 
Prematurity, 2008 and the American Policy 
Statement on Screening Examination of 
Premature Infants for Retinopathy of Prema-
turity, 2013.3 4
The UK guideline recommends phenyleph-
rine 2.5% and cyclopentolate 0.5%, 2–3 d; 
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but not recommended because a proprietary product is 
not available. In comparison, the American policy state-
ment does not provide any recommendations for suitable 
mydriatic agents and regimens.
This robust review of the literature evaluates the 
evidence for both the safety and efficacy aspects of mydri-
atic regimens used during ROP screening.
MethOds
One review author (LK) searched the published liter-
ature looking for reports on the safety and/or efficacy 
during 2017 and 2018.
databases used
The following databases were used: EMBASE, MEDLINE 
via Ovid, PubMed, Web of Science, Cochrane Library and 
Cochrane Neonatal Review Group and Google Scholar. 
Date restricted 1970 onwards. Refer to online appendix 1 
for Medline search strategy.
Other
Additional records were identified through reference 
review of sourced literature.
Keywords used
The following keywords were used ‘phenylephrine’, 
‘cyclopentolate’, ‘tropicamide’, ‘mydriasis’, ‘pupil dila-
tion’, ‘adverse effects’, ‘administration and dosage’, ‘eye 
drops’, ‘ophthalmic solutions’, ‘pupil’. Subject heading: 
‘infant, newborn, premature’, ‘efficacy’, ‘safety’. It was 
considered that the following were synonymous with 
mydriasis: pupil dilation and pupil dilatation.
Inclusion criteria
Participants are premature infants, interventions are 
mydriatic medicine administration, comparisons of effi-
cacy are between different mydriatic regimens, compar-
isons of safety are between baseline and any adverse 
effect, outcomes for efficacy are either pupil dilation 
measurements or successful eye examination, outcomes 
for safety are any adverse effects, study design includes all 
study designs including pilot and case reports. Full text is 
available in English.
exclusion criteria
Full text not available in English, published after 1970, 
commentary, letters to the editor, publications on; 
pain associated with ROP procedure, physiology and 
ophthalmic formulation; paediatric participants.
study selection
Screening and eligibility assessment was performed inde-
pendently in an unblinded standardised manner by one 
reviewer (LK). No data was meta-analysed due to the 
high variability of the mydriatic regimens.
data collection process
Included studies were entered into EndNote, and the 
‘remove duplicates’ function was utilised. Online trial 
registration for all intervention studies was accessed 
(when available) and study design was compared with 
publication results.
Studies that reported pupil dilation data were entered 
into Microsoft Excel and a forest plot was created using 
GraphPad PRISM (V.7.04). Some of the pupil dilation 
data needed to be converted into measurement (mm) 
and rounded to the nearest decimal point. Studies 
that reported blood pressure and heart rate data were 
collated in a Microsoft Word table. Some of the blood 
pressure results were converted into percentage increase 
or decrease.
data items
Information was extracted from each included trial on: 
(1) characteristics of trial participants (including gesta-
tional age, birth weight) and the trial’s inclusion and 
exclusion criteria; (2) type of intervention (mydriatic(s) 
used, concentration, number of administrations, timing 
of dosing; (3) type of outcome measure (including pupil 
dilation measurement, effects on cardiovascular, gastro-
intestinal, respiratory, dermal and CNS and other).
risk of bias
Cochrane methodology was used to assess risk of bias for 
RCTs and results analysed using Review Manager (V.5.3). 
ROBINS-1 tool was used to assess risk of bias for non-ran-
domised intervention trials, and observational studies 
were assessed for bias using the National Heart, Lung 
and Blood Institute (NHLBI) checklist.5
summary measures
Where available, the difference in means (±SD) data was 
obtained from the pupil dilation (efficacy) and safety 
measurements (eg, blood pressure, heart rate).
results
One hundred and eighty six studies were identified, and 
of these, 47 publications were included in the systematic 
review (figure 1). Efficacy and safety data were extracted 
from the publications, and safety data were further subcat-
egorised into themes of cardiovascular, gastrointestinal, 
respiratory, CNS, dermal and other effects (table 1). All 
trials occurred at a single centre.
Risk of bias for all studies are summarised in figure 2 
and in tables 2 and 3.
efficacy
Key findings
1. The majority of published data are from pilot studies 
that had a significant amount of unclear to high risk of 
bias; therefore, there is no strong evidence to support 
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Figure 1 Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses flow diagram.
2. There is a wide range of mydriatic concentrations and 
frequency of administration in the published litera-
ture.
3. Almost all mydriatic regimens included in this review 
demonstrated sufficient pupil dilation of above 5 mm 
(figure 3).
4. The regimen with the most convincing evidence is 
phenylephrine 1% and cyclopentolate 0.2%, 1 d of 
each.
5. Microdrop administration of mydriatic medicines are 
likely to sufficiently dilate the pupil.
Fifteen studies measured pupil dilation to ascertain 
efficacy and one publication (Neffendorf 2014) meas-
ured efficacy as a successful ROPEE. Participants were 
all premature infants and the number of participants in 
the studies ranged from 5 to 88. Study design was either 
RCT, quasi-RCT or cross-over controlled RCT; however, 
the majority of the studies were quasi-RCTs and all had 
small sample sizes. Within these studies, the mydriatic 
regimens, method of measuring pupil diameter, physio-
logical measures (eg, blood pressure, feed intolerance) 
all varied significantly. Because of this diverse range of 
mydriatic regimens and study methodology, compari-
sons across papers posed some difficulty and therefore 
highlights the need for robust evidence to guide clinical 
practice.
Additionally, within these 16 studies, there were 33 
different regimens using various combinations of phenyl-
ephrine, cyclopentolate and tropicamide (table 1).
Only three regimens did not achieve sufficient pupil 
dilation above 5 mm: monotherapy with phenylephrine 
10% (2 d and 2 microd)6 and tropicamide 0.5% (3 d).7 
However, all other regimens, irrespective of concen-
tration and frequency, did provide sufficient dilation 
(figure 3). Data from Isenberg (1984 March and July) 
is not included in figure 3, because net pupil dilation 
results were not available.8 9 Data from Wheatcroft (1993) 
was also unable to be used in figure 3 because SD results 
were not available.1
Overall, the efficacy studies had a significant amount of 
unclear bias. Of concern, the majority of these studies had 
unclear randomisation generation, allocation conceal-
ment, blinding of personnel and participants (figure 2).
safety
Key findings
1. The majority of safety specific data is from low level 
study design studies; therefore, there is limited evi-
dence to support clinical practice (figure 2 and ta-
bles 2 and 3).
2. There is a diverse range of safety aspects evaluating 
mydriatic safety.
3. Multiple measures were used to evaluate mydriatic 
safety.
Twenty-two studies investigated safety aspects of the 
mydriatic regimens (table 1). Within case reports, there 
were 30 adverse events post-mydriatic administration.
Participants in the safety studies and case reports were 
all premature infants. The safety study design was either 
RCT, non-randomised intervention, observational, 
retrospective audits or case reports. The majority of the 
studies were non-randmoised intervention studies, and 
the sample size between the safety studies ranged from 
7 to 1183. Within these studies, the mydriatic regimens, 
physiological measures (eg, blood pressure, feed intol-
erance) all varied significantly. This was similar for the 
case report analysis. Comparisons across papers created 
difficulty because of the variation in study design, low 




1. Systemic absorption of phenylephrine causes vasocon-
striction, resulting in increased blood pressure and 
tachycardia,10–12 whereas anticholinergics can cause 
transient bradycardia, followed by tachycardia, palpi-
tation and arrhythmias.13 Both increases and decreas-
es in blood pressure and heart rate were reported in 
the literature.
2. There is a wide range of both mydriatic regimens and 
blood pressure measures, therefore, making the inter-
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Table 1 Summary of characteristics and demographics for publications (excluding case reports)
Paper Design Regimen Mean (SD) GA Mean (SD) BW (g) Sample Size Efficacy Safety
Alshafei (2017)43 Observational 
prospective





P 2.5% (1d), T 0.5% (2 d) 32.3 (±3.3) weeks 1544 (±761) 20 ✓ C
C 0.5% (1d), T 0.5% (2 d) 34.6 (±3.6) weeks 1831 (±645) 19 ✓ C
Bonthala (2000)26 Non-randomised 
intervention





P 2.5%, C 0.5%, T 0.5% 
(1 d)
26–42 weeks 880–3440 10 ✓
P 2.5%, C 0.5%, T 0.5% 
(2 d)







P 2.5%, C 1% (3 d) 29.92 (±2.66) 
weeks
– 13 ✓ G
P 2.5%, T 1% (3 d) 29.23 (±1.59) 
weeks
– 13 ✓ G
P 1%, C 0.2% (3 d) 29.15 (±2.54) 
weeks







C 1% (2 d or 2 microd) 39.68 (±34.33) 
days
 – 16 ✓ C, D
P 10% (2 d or 2 microd) 22.83 (±21.39) 
days
– 18 ✓ C, D
T 0.5% (2 d or 2 microd) 28.78 (±26.89) 
days







C 0.25% (2 d) 31 (±2) weeks 1233 (±390) 6 G
C 0.5% (2 d) 31 (±2) weeks 1233 (±390) 8 G









C 0.5% (2 d) – 1198 (±220) 10 ✓ C
C 0.5%, T 0.5% (2 d) – 1227 (±220) 10 ✓ C











C 0.5% (2 d) – 1178 (±208) 12 ✓ C
P 1%, C 0.2% (2 d) – 1282 (±207) 12 ✓ C
P 2.5%, T 0.5% (2 d) – 1135 (±282) 12 ✓ C
Saline – – 6 ✓ C
Jiang (2016)15 Observational 
retrospective









– 28 ✓ C




– 28 ✓ C
Laws (1996)18 Observational 
prospective
P 2 5% (2d), C 0.5% (4 d) 27.1 (±2.4) 1003 (±332) 56 C
Lees (1981)16 Observational 
prospective





P 0.5%, T 0.5% (3 d) 26–37 weeks – 88 ✓





T 0.5% (3 d) – – 30 ✓





P 2.5%, T 1% (3 d) 32 (±0.5) 1569 (±98.7) 52 C
P 2.5%, T 0.5%, C 0.5% 
(3 d)
30.2 (±0.4) 1250.7 (±61.6) 30 C
Mirmanesh (1992)27 Non-randomised 
Intervention












5Kremer LJ, et al. BMJ Paediatrics Open 2019;0:e000448. doi:10.1136/bmjpo-2019-000448
Open access
Paper Design Regimen Mean (SD) GA Mean (SD) BW (g) Sample Size Efficacy Safety
Mitchell (2016)41 RCT P 1%, C 0.2% (3 d) 28.5 (±2.8) 1148 (±523) 25 G, R
Mitchell (2011)32 Observational 
prospective
P 1%, C 0.2% (3 d) 28.24 (±2.62) 1161 (±352) 50 R, C, G, N
Neffendorf (2015)47 Observational 
retrospective


















P 2.5%, C 0.5%, T 0.5% 
(1 d)
39.4 weeks 3150 10 ✓
P 2.5%, T 1% (1 d) 39.4 weeks 3150 10 ✓
P 2.5%, C 1% (2 d) 39.4 weeks 3150 10 ✓
C 1%, T 1% (1 d) 39.4 weeks 3150 10 ✓
P 2.5% (2 d) 39.4 weeks 3150 10 ✓
C 1% (2 d) 39.4 weeks 3150 10 ✓
T 1% (2 d) 39.4 weeks 3150 10 ✓






P 2.5%, T 0.75% (2d) 30.5 weeks 1241.9 21 ✓ C






P 1%, C 0.2% (1 d) 30.49 (2.34) 1368 (438.99) 70 ✓ R
P 1%, C 0.2% (3 d) 30.49 (2.34) 1368 (438.99) 70 ✓ R
Rosales (1981)22 Observational 
prospective
P 2.5%, T 0.5% (3 d) – – 10 C
Rush (2004)28 Observational 
prospective







P 2.5%, T 1% (2 d) 28.0 (1.9) weeks 1022 (226) 10 ✓ C
P 2.5%, T 0.5% (2 d) 28.3 (1.6) weeks 1115 (281) 10 ✓ C







P 1%, C 0.2% (1 d) 28.7 (2.6) weeks – 5 ✓
P 1%, C 0.2% (2 d) 28.7 (2.6) weeks – 10 ✓






P 2.5%, C 0.5%, (2 d) 29.8 weeks 1238 26 ✓
P 2.5%, C 0.5%, (2 microd) 29.8 weeks 1238 26 ✓
Efficacy was identified if authorsmeasured pupil dilation or successful retinopathy of prematurity eye examinations. Safety was determined if physiological 
measurements were taken.
BW, birth weight; C, cardiovascular; C, cyclopentolate;D, dermal; G, gastrointestinal; GA, gestational age; P, phenylephrine; R, respiratory;RCT, randomised 
controlled trial; T, tropicamide; d, standard drop; microd, microdrop.
Table 1 Continued
3. Clinical significance is difficult to determine due to 
inability to adjust for confounders and gestational age 
of infants.
4. No statistically significant changes in blood pressure 
and heart rate were seen with microdrop administra-
tion.
5. Case reports highlight serious adverse effects such as 
cardiopulmonary arrest and pulseless.
A number of authors have investigated blood pressure 
and heart rate adverse effects associated with mydriatics 
(table 4). All results in table 4 are after mydriatic adminis-
tration, but before ROPEE, which is important as ROPEE 
is a confounder due to the oculocardio reflex-mediated 
reduction in heart rate, of approximately 10%, following 
ROPEE.14
Evidence collected from a retrospective audit, with a 
sample size of 1254 premature infants, showed significant 
increases in blood pressure after administration of phenyl-
ephrine 0.5% and tropicamide 0.5%, 3 d (mean diastolic 
blood pressure 8.5% (p=0.04), mean systolic blood pres-
sure 5.4% (p=0.078)).15 This was compared with other 
cardiovascular related data sets which were from pilot 
studies, and within these eight different regimens, statis-
tically significant increases in mean blood pressure were 
seen. The range of these increases in mean blood pressure 
from baseline ranged from 5.1% (no SD) to 22.8±17.4% 
(table 4).6 10 16 17 Because multiple mydriatic regimens 
were used in these studies, no causative regimen was iden-
tified as having more of an effect on blood pressure.
A reduction in blood pressure was also identified in 
some studies. Four of these mydriatic regimens in pilot 
studies found statistically significant reductions in mean 
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Figure 2 Cochrane tool risk of bias summary for 
randomised controlled trial (RCT) or quazi-RCT studies. 
Review authors' judgements about each risk of bias item for 
each included study. Key: ‘–’ indicates high risk of bias; ‘?’ 
indicates unclear risk of bias; ‘+’ indicates low risk of bias.





The study has some 
important problems.
The study is judged to be at 
serious risk of bias across the 
confounding and selection of 
participants domains, but not at 




The study has some 
important problems.
The study is judged to be at 
serious risk of bias in classification 
of intervention domain, but not at 
critical risk of bias in any domain.
Isenberg 
(1984 July)9
The study provides 
sound evidence for 
a non-randomised 
study but cannot 
be considered 
comparable to a 
well-performed 
randomised trial.
The study is judged to be at low 
or moderate risk of bias for all 
domains, except for bias due 




The study provides 
sound evidence for 
a non-randomised 
study but cannot 
be considered 
comparable to a 
well-performed 
randomised trial.
The study is judged to be at 
low or moderate risk of bias for 
most domains; however, there 
was insufficient information to 
determine bias in deviation from 
intervention, missing data and 
outcome measures.
Ogut (1996)48 The study provides 
sound evidence for 
a non-randomised 
study but cannot 
be considered 
comparable to a 
well-performed 
randomised trial.
The study is judged to be at 
low or moderate risk of bias for 
most domains; however, there 
was insufficient information 
to determine bias in selection 
of participants, deviation from 




The study provides 
sound evidence for 
a non-randomised 
study but cannot 
be considered 
comparable to a 
well-performed 
randomised trial 
because there is a 
significant lack of 
information in the 
methods section of 
the paper.
The study is judged to be at 
low or moderate risk of bias for 
most domains; however, there 
was insufficient information 
to determine bias in selection 
of participants, deviation from 
intended intervention, missing data 
and the reported results.
Table 3 National Heart Lung and Blood Institute overall 










Clinical significance of all of the blood pressure results 
is difficult to determine without directly comparing the 
results to the individual gestational age of the infant and 
adjusting for confounders.
Statistically significant changes in heart rate only 
occurred when two anticholinergic medicines were used. 
An increase of the mean heart rate of 3.7% occurred 
following cyclopentolate 0.5% (1 d) and tropicamide 
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Figure 3 Pupil dilation results (mean and 95% CI) for 
treatment arms in RCTs, including quasi-RCT and cross-
over RCT. The dotted line is the estimated pupil dilation (5 
mm) that is required for an ophthalmologist to perform a 
successful retinopathy of prematurity eye examinations. C, 
cyclopentolate; d, drop; micro, microdrop; P, phenylephrine; 
RCT, randomised controlled trial; T, tropicamide.
heart rate of 10%±10.6% occurred following phenyleph-
rine 2.5%, tropicamide 0.5% and cyclopentolate 0.5% (2 
d) administration.20
There were no significant cardiovascular changes 
recorded in the microdrop groups, which is likely 
explained by the lower total dose leading to minimal 
systemic absorption.18
Blood pressure and heart rate results from Caputo 
(1982),9 Chew (2005),15 Luo (2014),21 Mirmanesh 
(1992),22 Pharmonvaechavan (2012),23 Rosales (1981),24 
Rush (2004)25 were not able to be included in the analysis 
because SD or SE and p values were not included in the 
publication. Blood pressure results from Rosales (1981)24 
were not able to be included in the analysis because SD 
and p values were not included in the publication. Ogut 
(1996)26 results were not able to be included because 
p values were not presented. Luo (2014)21 commented 
that no infants had bradycardia, and Lux’s (2016)27 study 
design intended to collect data on pulse rate and blood 
pressure but did not provide results for this.
Very specific cardiovascular monitoring occurred in a 
study of 42 premature infants, where mean anterior and 
middle cerebral artery blood flow, heart rate, end diastolic 
velocity (anterior and middle cerebral artery) and blood 
pressure was measured. Results from this observational 
study found no statistically significant results; however, 
this study may have been underpowered to detect a statis-
tically significant result.25
Fourteen cardiovascular adverse events were docu-
mented in case reports (table 5). All infants had phenyl-
ephrine administered; however, due to the variation in 
regimens, no themes of likely causative regimens were 
determined. Tachycardia and bradycardia were the most 
common reports, and cardiopulmonary arrest and pulse-
less being the most clinically significant.
Gastrointestinal
Key findings
1. Phenylephrine can cause vasoconstriction of the blood 
supply to the gut, and anticholinergic effect on the gut 
reduces peristalsis; hence, both mechanisms of actions 
affect the gastrointestinal system.
2. Feed intolerance, abdominal distention, ileus and 
NEC are gastrointestinal adverse effects associated 
with mydriatic use.
3. All cases of gastrointestinal adverse effects had phenyl-
ephrine administered, and the majority had cyclopen-
tolate. Only one case involved the use of tropicamide.
4. Three infants have died with complications associated 
with NEC, possibly linked with mydriatic use.
5. All safety and case reports had regimens where stan-
dard drops were used.
Reduced gastric volume, increased abdominal girth, 
increased feed intolerance and increased incidence of 
NEC were some of the gastrointestinal adverse effects inves-
tigated by authors (table 6). Additionally, Jiang (2016)10 
found that approximately 10% of infants developed NEC 
following phenylephrine 0.5% and tropicamide 0.5% (3 d) 
administration (p<0.01), and new cases of upper digestive 
tract haemorrhage also increased (n=139, p<0.00).10
Antral and duodenal motor activity and gastric emptying, 
pre and post phenylephrine 2.5% and cyclopentolate 
0.5% (2 d) administration was measured in 11 premature 
infants.26 Duodenal motor contractions decreased nearly 
fourfold after mydriatic instillation and gastric emptying 
was significantly delayed (table 5).26
Results from an intervention study (n=10), demon-
strated a reduction in gastric acid secretion of approxi-
mately 58% following cyclopentolate 0.5% administration 
(p<0.01) (table 6).16 This is compared with a RCT (n=25), 
where gastric residuals increased following phenylephrine 
1% and cyclopentolate 0.2% (3 d) administration (p=0.01) 
(table 6).28
No statistically significant results from a RCT (n=39) for 
abdominal girth or feed intolerance occurred following the 
administration of phenylephrine 2.5% and cyclopentolate 
1% (3 d) or phenylephrine 2.5% and tropicamide 1% (3 
d) or phenylephrine 1% and cyclopentolate 0.2% (3 d).15
Abdominal distention (n=7), NEC (n=4), transient ileus 
(n=3) and feed intolerance (n=3) are the most common 
adverse effects documented in case reports (table 7). 
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Table 4 Blood pressure and heart rate adverse effects for studies with p values, percentage change from baseline
Paper Regimen mBP (mm Hg) ±SD mDBP (mm Hg) ±SD mSBP (mm Hg) ±SD mHR (beats/min)±SD
Bonthala (2000)8 P 1%, C 0.2% (2 d) ↓ 11.5±5.8%* – – ↑ 0.6±1.2%*
Bolt (1992)7
 
P 2.5% (1d), T 0.5% (2 d) ↓ 4% – – ↓ 1%







C 1% (2 d) ↑ 16.2%±2.2%*† – – ‡
C 1% (2 microd) ↓ 1%±2.3%*† – – ‡
P 10% (2 d) ↑ 8%±0.2%*† – – ‡
P 10% (2 microd) 0±1.9%* – – ‡
T 0.5% (2 d) ↑ 17.5%±0.2%*† – – ‡




C 0.5% (2 d) ↓10%±12%† – – ↑ 7.5%±18%
C 0.5%, T 0.5% (2 d) ↓ 10%±12%† – – ↑ 7.5%±18%




C 0.5% ↓ 13.2%   ↓ 3.3%
P 1%, C 0.2% ↓ 3.8%   ↓ 4.3%
P 2.5%, T 0.5% ↑ 19.6%   ↓ 5.2%
Jiang (2016)10 P 0.5%, T 0.5% (3 d) – ↑ 8.5*† ↑ 5.4%*§ –
Khoo (2000)17
 
P 1%, C 0.2% (3 d) ↑ 3.7% −1% ↑ 0.8% ↓ 4.5%
P 2.5%, T 0.5% (3 d) ↓ 0.4% ↓ 0.3% ↓ 1.2% ↓ 6.6%
Laws (1996)11 P 2.5% (2d), C 0.5% (4 d) – ↑ 4.8%* ↑ 5%* ↓ 1.3%*
Lees (1981)12 P 2.5%, T 0.5% (1 d) ↑ 19.4%† ↑ 19.1%† ↑ 17.1%† 0%
Merritt (1981)49
 
P 2.5%, T 1% (3 d) – – 0% –
P 2.5%, T 0.5%,
C 0.5% (3 d)
– – 0% –
Phamonvaechavan 
(2012)23




P 2.5%, T 1% (2 d) ↓ 17.1%±10.4%† – – –
P 2.5%, T 0.5%,
C 0.5% (2 d)
↑ 22.8%±17.4%† – – ↑ 10.0%±10.6%†
P 1%, T 1% (2 d) ↑ 7.7%±9.3%† – – –




C, cyclopentolate; P, phenylephrine; T, tropicamide; d, standard drop;mDBP, mean diastolic blood pressure; mHR, mean heart rate; mSDP, mean systolic blood 
pressure; microd, microdrop.
Table 5 Summary of cardiovascular events
Paper Regimen Tachycardia Bradycardia Other
Ahmad (2016)50 P 1%, C 0.2%, (unknown d) 2 2 Premature atrial contractions (2)
Ozgun (2014)29 P 1.25%, C 0.5% (2 d) 1  
Socarras (2017)51 P 2.5%, T(unknown concentration) (2 d) 1 Arterial hypertension (1)
Ahmad (2016)50 P 1%, C0.2% (3 d) Cardiopulmonary arrest (1)
Wood (2009)52 P 1%, C 0.2% (1–2 d) 2 Pulseless (1)
Siu (2011)30 P 2.5%, C 1% (2 d) 1  
C, cyclopentolate;P, phenylephrine; T, tropicamide; d, standard drop.
respiratory
Key findings
1. Unwanted respiratory effects could occur via alpha-ag-
onist mediated activity. Phenylephrine has a stimulato-
ry effect on increasing airway smooth muscle tension, 
which leads to bronchoconstriction, reduced oxygen 
saturations and apnoea.
2. Infants with bronchopulmonary dysplasia (BPD) are 
more likely to experience respiratory adverse effects 
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Table 6 Publications providing data on gastric volume, abdominal girth and feed intolerance
Paper Regimen
Mean gastric volume±SD (μmol/
kg/hour)




Chew (2005)15 P 2.5%, C 1% (3 d) – 25.2±1.6 50%
P 2.5%, T 1% (3 d) – 27.1±2.0 25%
P 1%, C 0.2% (3 d) – 27.1±2.9 25%
Isenberg (1985)16 C 0.25% (2 d) 10±7 – –
C 0.5% (2 d) Approx. 2.5±1* – –





C, cyclopentolate;P, phenylephrine; T, tropicamide; d, standard drop.





CARM (2014)31 P 2.5%, C 0.5% 
(3 d)
1







































Lim (2003)53 P 1%, C 0.2% (3 d) Transient 
ileus (1)
C, cyclopentolate; CARM, Centre for Adverse Reactions Monitoring; NEC, 
necrotising enterocolitis;P, phenylephrine; T, tropicamide; d, standard drop.
Table 8 Publications providing data on respiratory adverse 
effects
Paper Regimen Adverse effect
Alshafei (2017)6 P 2.5%, T 
0.5% (3 d)
No adverse effect on oxygen 
saturation, not statistically 
significant




Mitchell (2016)28 P 1%, C 0.2% 
(3 d)
Desaturations more likely 
in oxygen therapy group 
(p=0.01)
Mirmanesh (1992)22 P 2.5% (3 d) Infants with BPD;
 ► Reduction in mean 
pulmonary compliance 
(p<0.03)
 ► Increased mean total 
resistance (p<0.01)




Not identified Apnoea: one infant.
C, cyclopentolate;P, phenylephrine; T, tropicamide; d, standard drop.
3. Infants on oxygen support are more likely to have 
higher serum concentrations of cyclopentolate than 
those not on oxygen support.
4. The most common adverse effects identified in case 
reports are apnoea and desaturation.
5. All safety and case reports had regimens where stan-
dard drops were used.
Oxygen saturation and apnoea effects were investi-
gated in just a few studies (table 8). Results from a pilot 
observational study (n=42) demonstrated no change in 
oxygen saturations following the use of phenylephrine 
2.5% and tropicamide 0.5% (3 d) (p>0.05) (table 8).6 
This compares audit data from 1183 infants, where signif-
icant increases in apnoea were seen following signifi-
cantly lower doses of phenylephrine 0.5% and equal dose 
of tropicamide 0.5% (3 d) (p<0.05) (table 6).10
Following phenylephrine 2.5% (3 d) administration, 
infants with BPD are more likely to experience a reduc-
tion in mean pulmonary compliance (p<0.03), increased 
mean total resistance (p<0.01) and reduced expiratory 
airflow (p<0.03), compared with infants without BPD.20
Cyclopentolate serum concentrations were measured 
following cyclopentolate 0.2% (3 d) administration.28 
Results show that infants who were receiving oxygen 
therapy, had significantly higher cyclopentolate concen-
trations, than infants who were not receiving oxygen 
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Table 9 Summary of respiratory events
Paper Regimen Apnoea Desaturation Other
Sarici (2001)45 P 2.5%, C 0.5% (2 d) 1
Degirmencioglu (2014)47 P 2.5%, T 0.5% (3 d) 1
Wood (2009)52 P 1%, C 0.2% (1–2 d) 1 Shallow breathing (1)
Wood (2009)52 P 1%, C 0.2% (1–2 d) 1
CARM (2002)35 P 1%, C 0.5% (1 d) 1 1
Siu (2011)30 P 2.5%, C 1% (2 d) 1
Kim (2015)46 P 2.5%, T 0.5% (2 d) 1 Mild wheezing (1)
Kim (2015)46 P 2.5%, T 0.5% (2 d) Bronchospasm (1)
Mild wheezing (1)
Ozgun (2014)29 P 1.25%, C 0.5% (2 d) Tachyapnoea (1)
C, cyclopentolate;P, phenylephrine; T, tropicamide; d, standard drops.
concentrations and who were receiving oxygen therapy 
also were more likely to have desaturations (p=0.01).28
Lux’s (2016)27 study design intended to collect data on 
oxygen saturation and respiratory frequency but did not 
provide results for this.27
Thirteen respiratory associated events are documented 
with the most common are apnoea (n=5), desaturations 
(n=3) and other respiratory events (n=5) (table 9).
Central nervous system
No safety data on CNS adverse effects has been published. 
The only CNS data available are case reports and involve 
seizures (n=5) and anticholinergic syndrome (n=1).31–34 
All cases involved the use of cyclopentolate 0.5%. The 
mechanism for seizure activity following alpha agonist and 
anticholinergic agents is unknown.
dermal
Three infants experienced periorbital pallor following 
phenylephrine 2.5% and tropicamide 0.5% (1 d).12 
Conversely, skin flushing was observed following cyclopen-
tolate 1% (2 d) and phenylephrine 10% (2 d) administra-
tion.18
A mechanism for skin flushing is unknown, and skin 
flushing seems very unusual considering the mechanism of 
action of phenylephrine. If phenylephrine eye drop excess 
is not wiped away from the eye area, this allows for phenyl-
ephrine to be absorbed dermally. Subsequent vasoconstric-
tion occurs which results in periorbital pallor.
Ten dermal events have been reported, and these include 
eyelid swelling (n=4) and periorbital pallor (n=6).35–38
Other
There were a few other case reports identified which 
did not fit into the above themes, and the cases involved 
cutis marmorata, leukopaenia, neutropaenia and renal 
failure.29 39
dIsCussIOn
This review has identified that low dose mydriatics 
have comparable efficacy to larger doses; therefore, 
irrespective of mydriatic regimen, sufficient pupil dila-
tion occurs at low doses.
Of all the regimens reviewed for efficacy, phenyleph-
rine 1% and cyclopentolate 0.2% (1–2 d) is the lowest 
combination dose that provides sufficient pupil dila-
tion.40–42 However, phenylephrine 2.5% and cyclopen-
tolate 0.5% (2–3 d) is the recommended regimen in the 
UK guideline,3 although there is no known publication 
evaluating the efficacy of the three-drop regimen. This 
dose seems unnecessarily high considering the current 
body of knowledge about efficacy. With regard to safety, 
results from a retrospective audit of 138 premature 
infants who underwent ROPEE’s using the UK guide-
line regimen, highlighted six cases of harm ranging 
from apnoea, desaturations and NEC,43 and there is an 
unpublished case of death associated with NEC31 and a 
case of seizure.33
Although the extent of mydriatic harm has not been 
fully investigated, a few studies signal the potential for 
cardiovascular, gastrointestinal and respiratory adverse 
effects. It is very likely that our most vulnerable prema-
ture infants with pre-existing medical conditions are 
the ones who are more likely to experience adverse 
effects associated with mydriatics and less likely to be 
able to compensate for any medicine related harms. 
Medical practice is evolving in both the developed and 
low-income and middle-income countries, and as the 
ROPEE standard of care is being extended, it is likely 
that there will be an increase in adverse effects post-
ROPEE in centres who are using high-dose mydriatic 
regimens.
Simple concepts that need further investigations are 
giving low concentrations as a single microdrop. This 
method would reduce the risk of mydriatic exposure to 
the systemic circulation.1 42
Infants with dark irides may also need special dosing 
consideration, because it is hypothesised that higher 
doses may need to be administered in people with 
dark pigmented iris.15 17 44 This implication for dosing 
requirements could also have potential increased risks 
associated with side effects and subsequent harm. 
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adjustment recommendations based on iris colour. 
Further research is required to ascertain this potential 
association.
And lastly, readily available commercial products are 
prepared at higher concentrations than what is needed, 
and current packaging is suitable for adult dose admin-
istration and not neonatal dosing. Further research on 
appropriate formulations and packaging for commer-
cial products needs to occur.
limitations
Limitations of this systematic review are (1) the non-ran-
domised trials included in the review were not designed 
as comparative studies, (2) case reports were assessed as 
reported and no independent assessment was carried 
out for causality, (3) there was a significant amount 
of unclear bias in the publications and (4) papers not 
available in English were not included in this review.
An assumption was made that if microdrop adminis-
tration was not specified and that standard drops were 
administered.
Confounders, such as pre-existing medical condi-
tions and pain associated with ROPEE, were often not 
mentioned in the publications included in the analysis.
Number of case reports are likely to be much higher. 
It is estimated that approximately 10% of ADRs are ever 
reported, and very few of these make it to publication.
COnClusIOns
Current international guideline seems unnecessarily 
high, especially when the reviewed literature suggest 
that lower doses are effective. All studies investigating 
efficacy were underpowered due to limited sample size; 
however, the lowest effective regimen is phenylephrine 
1% and cyclopentolate 0.2% (1 d).42 Microdrop admin-
istration of this and other regimens would further 
increase the safety profile; however, efficacy may not be 
ensured. Further investigation and validation needs to 
occur.
In conclusion, low doses of mydriatics appear to be 
effective and are likely to be associated with a safer 
adverse effect profile.
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